所有图片(1)
About This Item
经验公式(希尔记法):
C28H22Cl3NO4
CAS号:
分子量:
542.84
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.32
推荐产品
质量水平
方案
≥97% (HPLC)
表单
powder
储存条件
desiccated
颜色
white
溶解性
DMSO: 10 mg/mL, clear
储存温度
2-8°C
SMILES字符串
CC(C)c1onc(c1COc2ccc(\C=C\c3cccc(c3)C(O)=O)c(Cl)c2)-c4c(Cl)cccc4Cl
InChI
1S/C28H22Cl3NO4/c1-16(2)27-21(26(32-36-27)25-22(29)7-4-8-23(25)30)15-35-20-12-11-18(24(31)14-20)10-9-17-5-3-6-19(13-17)28(33)34/h3-14,16H,15H2,1-2H3,(H,33,34)/b10-9+
InChI key
BYTNEISLBIENSA-MDZDMXLPSA-N
一般描述
GW4064是合成异恶唑,用于揭示类法尼醇X受体(FXR)的细胞结构和生理功能。是雌激素受体相关受体(ERR)激动剂。
应用
GW4064用于:
- 研究其保护小鼠肝脏免受脂多糖(LPS)诱导炎症和细胞凋亡影响的能力
- 研究其抑制脂多糖(LPS)引起回肠粘膜损伤的能力
- 处理回肠外植体
生化/生理作用
GW4064 是一种 FXR 激动剂。GW4064 是孤儿核受体 FXR 的强效 (EC50 = 15 nM) 非甾体激动剂。它对其他核受体(包括高达1 mM 的 RAR)没有活性,是研究 FXR 参与多种生物活动的重要工具。
特点和优势
该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处。
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Synthetic FXR Agonist GW4064 Is a Modulator of Multiple G Protein-Coupled Receptors
Singh N, et al.
Molecular Endocrinology, 28(5), 659-673 (2014)
Xiang Jiang et al.
Journal of autoimmunity, 90, 64-75 (2018-02-13)
Mucosal-associated invariant T (MAIT) cells are novel innate-like T cells constituting a significant proportion of circulating and hepatic T cells. Herein, we extensively examine the phenotypical and functional alterations of MAIT cells and their regulation in a cohort of 56
Qixiao Zhai et al.
Food & function, 10(3), 1455-1464 (2019-02-16)
The management of lead (Pb) exposure and toxicity remains a major public health priority worldwide. In our previous study, the probiotic strain Lactobacillus plantarum CCFM8661 prevented Pb absorption in mice via intestinal sequestration. This follow-up study aimed to evaluate the
Bile acid administration elicits an intestinal antimicrobial program and reduces the bacterial burden in two mouse models of enteric infection
Tremblay S, et al.
Infection and Immunity, 85(6), e00942-e00916 (2017)
Mingyi Liu et al.
Frontiers in pharmacology, 11, 375-375 (2020-04-16)
Berberine, a quinoline alkaloid, can be used in combination with statins to enhance hypolipidemic effects and reduce the dose and side effects of statins. The hypolipidemic effects of statins in the liver are mainly regulated by organic anion transporting polypeptides
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门